FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904387510> ?p ?o ?g. }

• W2904387510 endingPage "36877" @default.
• W2904387510 startingPage "36867" @default.
• W2904387510 abstract "// Monika Toma 1 , Monika Witusik-Perkowska 2 , Marzena Szwed 3 , Robert Stawski 4 , Janusz Szemraj 2 , Malgorzata Drzewiecka 1 , Margaret Nieborowska-Skorska 5 , Maciej Radek 6 , Pawel Kolasa 7, 8 , Ksenia Matlawska-Wasowska 9 , Tomasz Sliwinski 1 and Tomasz Skorski 5 1 Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland 2 Department of Medical Biochemistry, Medical University of Lodz, Lodz, Poland 3 Department of Medical Biophysics, University of Lodz, Lodz, Poland 4 Department of Clinical Physiology, Medical University of Lodz, Lodz, Poland 5 Department of Microbiology and Immunology, Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA 6 Department of Neurosurgery, Surgery of Spine and Peripheral Nerves, Medical University of Lodz, University Hospital WAM-CSW, Lodz, Poland 7 Department of Neurosurgery, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland 8 Social Sciences Academy in Lodz, Lodz, Poland 9 Division of Pediatric Research, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, NM, USA Correspondence to: Tomasz Sliwinski, email: tomasz.sliwinski@biol.uni.lodz.pl Tomasz Skorski, email: tskorski@temple.edu Keywords: glioblastoma; PARP inhibitor; LIG4; alkylating agent; synthetic lethality Received: June 30, 2018      Accepted: November 16, 2018      Published: December 07, 2018 ABSTRACT Cancer cells often accumulate spontaneous and treatment-induced DNA damage i.e. potentially lethal DNA double strand breaks (DSBs). Targeting DSB repair mechanisms with specific inhibitors could potentially sensitize cancer cells to the toxic effect of DSBs. Current treatment for glioblastoma includes tumor resection followed by radiotherapy and/or temozolomide (TMZ) – an alkylating agent inducing DNA damage. We hypothesize that combination of PARP inhibitor (PARPi) with TMZ in glioblastoma cells displaying downregulation of DSB repair genes could trigger synthetic lethality. In our study, we observed that PARP inhibitor (BMN673) was able to specifically sensitize DNA ligase 4 (LIG4)-deprived glioblastoma cells to TMZ while normal astrocytes were not affected. LIG4 downregulation resulting in low effectiveness of DNA-PK–mediated non-homologous end-joining (D-NHEJ), which in combination with BMN673 and TMZ resulted in accumulation of lethal DSBs and specific eradication of glioblastoma cells. Restoration of the LIG4 expression caused loss of sensitivity to BMN673+TMZ. In conclusion, PARP inhibitor combined with DNA damage inducing agents can be utilized in patients with glioblastoma displaying defects in D-NHEJ." @default.
• W2904387510 created "2018-12-22" @default.
• W2904387510 creator A5008146400 @default.
• W2904387510 creator A5024089702 @default.
• W2904387510 creator A5025976446 @default.
• W2904387510 creator A5026236861 @default.
• W2904387510 creator A5046316649 @default.
• W2904387510 creator A5049450086 @default.
• W2904387510 creator A5050879108 @default.
• W2904387510 creator A5054329930 @default.
• W2904387510 creator A5063022331 @default.
• W2904387510 creator A5063736852 @default.
• W2904387510 creator A5066651403 @default.
• W2904387510 creator A5072541705 @default.
• W2904387510 date "2018-12-07" @default.
• W2904387510 modified "2023-10-17" @default.
• W2904387510 title "Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent" @default.
• W2904387510 cites W1973268287 @default.
• W2904387510 cites W1985775217 @default.
• W2904387510 cites W1989006164 @default.
• W2904387510 cites W1998941426 @default.
• W2904387510 cites W2009007206 @default.
• W2904387510 cites W2014091491 @default.
• W2904387510 cites W2025329130 @default.
• W2904387510 cites W2056848326 @default.
• W2904387510 cites W2079932549 @default.
• W2904387510 cites W2083431317 @default.
• W2904387510 cites W2083960841 @default.
• W2904387510 cites W2086038769 @default.
• W2904387510 cites W2096287682 @default.
• W2904387510 cites W2117692326 @default.
• W2904387510 cites W2123588904 @default.
• W2904387510 cites W2131670056 @default.
• W2904387510 cites W2158649478 @default.
• W2904387510 cites W2166469535 @default.
• W2904387510 cites W2169703537 @default.
• W2904387510 cites W2171147062 @default.
• W2904387510 cites W2179105349 @default.
• W2904387510 cites W2295859676 @default.
• W2904387510 cites W2308934048 @default.
• W2904387510 cites W2366536035 @default.
• W2904387510 cites W2526969304 @default.
• W2904387510 cites W2610261021 @default.
• W2904387510 cites W2767643541 @default.
• W2904387510 cites W2785336226 @default.
• W2904387510 cites W2804063283 @default.
• W2904387510 cites W919607714 @default.
• W2904387510 doi "https://doi.org/10.18632/oncotarget.26409" @default.
• W2904387510 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6305145" @default.
• W2904387510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30627327" @default.
• W2904387510 hasPublicationYear "2018" @default.
• W2904387510 type Work @default.
• W2904387510 sameAs 2904387510 @default.
• W2904387510 citedByCount "8" @default.
• W2904387510 countsByYear W29043875102019 @default.
• W2904387510 countsByYear W29043875102020 @default.
• W2904387510 countsByYear W29043875102021 @default.
• W2904387510 countsByYear W29043875102022 @default.
• W2904387510 countsByYear W29043875102023 @default.
• W2904387510 crossrefType "journal-article" @default.
• W2904387510 hasAuthorship W2904387510A5008146400 @default.
• W2904387510 hasAuthorship W2904387510A5024089702 @default.
• W2904387510 hasAuthorship W2904387510A5025976446 @default.
• W2904387510 hasAuthorship W2904387510A5026236861 @default.
• W2904387510 hasAuthorship W2904387510A5046316649 @default.
• W2904387510 hasAuthorship W2904387510A5049450086 @default.
• W2904387510 hasAuthorship W2904387510A5050879108 @default.
• W2904387510 hasAuthorship W2904387510A5054329930 @default.
• W2904387510 hasAuthorship W2904387510A5063022331 @default.
• W2904387510 hasAuthorship W2904387510A5063736852 @default.
• W2904387510 hasAuthorship W2904387510A5066651403 @default.
• W2904387510 hasAuthorship W2904387510A5072541705 @default.
• W2904387510 hasBestOaLocation W29043875101 @default.
• W2904387510 hasConcept C134935766 @default.
• W2904387510 hasConcept C2776194525 @default.
• W2904387510 hasConcept C2778502085 @default.
• W2904387510 hasConcept C2993838110 @default.
• W2904387510 hasConcept C502942594 @default.
• W2904387510 hasConcept C509550671 @default.
• W2904387510 hasConcept C54355233 @default.
• W2904387510 hasConcept C552990157 @default.
• W2904387510 hasConcept C71924100 @default.
• W2904387510 hasConcept C86803240 @default.
• W2904387510 hasConceptScore W2904387510C134935766 @default.
• W2904387510 hasConceptScore W2904387510C2776194525 @default.
• W2904387510 hasConceptScore W2904387510C2778502085 @default.
• W2904387510 hasConceptScore W2904387510C2993838110 @default.
• W2904387510 hasConceptScore W2904387510C502942594 @default.
• W2904387510 hasConceptScore W2904387510C509550671 @default.
• W2904387510 hasConceptScore W2904387510C54355233 @default.
• W2904387510 hasConceptScore W2904387510C552990157 @default.
• W2904387510 hasConceptScore W2904387510C71924100 @default.
• W2904387510 hasConceptScore W2904387510C86803240 @default.
• W2904387510 hasIssue "96" @default.
• W2904387510 hasLocation W29043875101 @default.
• W2904387510 hasLocation W29043875102 @default.
• W2904387510 hasLocation W29043875103 @default.
• W2904387510 hasLocation W29043875104 @default.

• next